文献速递神经MR

波谱成像在灌注MRI鉴别常见恶性脑肿瘤中的附加价值

Added Value of Spectroscopy to Perfusion MRI in the Differential Diagnostic Performance of Common Malignant Brain Tumors.
PubMed 文献 · AJNR Am J Neuroradiol · 2018-07-26

研究纳入2013年1月至2016年1月55例经组织病理学证实的淋巴瘤、胶质母细胞瘤和转移瘤患者,分析灌注参数与波谱浓度比值的单独及最优组合分类器。波谱联合灌注的最优组合分类器显著提高了鉴别诊断敏感度(82.1%升至95.7%)和特异度(92.7%升至100%、83.3%升至97.0%和100%)。

要点

  • 最大信号强度恢复百分比联合Cho/NAA鉴别淋巴瘤与胶质母细胞瘤和转移瘤,敏感度从82.1%升至95.7%。
  • 相对CBV联合Cho/NAA鉴别胶质母细胞瘤与淋巴瘤和转移瘤,特异度从92.7%升至100%。
  • 最大信号强度恢复百分比联合乳酸/Cr或Cho/Cr鉴别转移瘤与淋巴瘤和胶质母细胞瘤,特异度分别从83.3%升至97.0%和100%。

核心结论

  • 波谱通过最优组合分类器为灌注提供附加性能价值,显著提高这些常见脑肿瘤的鉴别诊断性能。

研究设计与样本

  • 2013年1月至2016年1月连续纳入55例经组织病理学证实的淋巴瘤、胶质母细胞瘤和转移瘤患者,分析灌注参数(最大相对CBV、最大信号强度恢复百分比)和波谱浓度比值(乳酸/Cr、Cho/NAA、Cho/Cr、脂质/Cr)的单独及最优组合。

诊断标准与关键数值

  • 最大信号强度恢复百分比联合Cho/NAA鉴别淋巴瘤与胶质母细胞瘤和转移瘤,敏感度从82.1%升至95.7%;相对CBV联合Cho/NAA鉴别胶质母细胞瘤与淋巴瘤和转移瘤,特异度从92.7%升至100%;最大信号强度恢复百分比联合乳酸/Cr鉴别转移瘤与淋巴瘤和胶质母细胞瘤,特异度从83.3%升至97.0%;最大信号强度恢复百分比联合Cho/Cr鉴别转移瘤与淋巴瘤和胶质母细胞瘤,特异度从83.3%升至100%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Perfusion and spectroscopic MR imaging provide noninvasive physiologic and metabolic characterization of tissues, which can help in differentiating brain tumors. We investigated the diagnostic role of perfusion and spectroscopic MR imaging using individual and combined classifiers of these modalities and assessed the added performance value that spectroscopy can provide to perfusion using optimal combined classifiers that have the highest differential diagnostic performance to discriminate lymphomas, glioblastomas, and metastases.

MATERIALS AND METHODS: From January 2013 to January 2016, fifty-five consecutive patients with histopathologically proved lymphomas, glioblastomas, and metastases were included after undergoing MR imaging. The perfusion parameters (maximum relative CBV, maximum percentage of signal intensity recovery) and spectroscopic concentration ratios (lactate/Cr, Cho/NAA, Cho/Cr, and lipids/Cr) were analyzed individually and in optimal combinations. Differences among tumor groups, differential diagnostic performance, and differences in discriminatory performance of models with quantification of the added performance value of spectroscopy to perfusion were tested using 1-way ANOVA models, receiver operating characteristic analysis, and comparisons between receiver operating characteristic analysis curves using a bivariate χ2, respectively.

RESULTS: The highest differential diagnostic performance was obtained with the following combined classifiers: maximum percentage of signal intensity recovery-Cho/NAA to discriminate lymphomas from glioblastomas and metastases, significantly increasing the sensitivity from 82.1% to 95.7%; relative CBV-Cho/NAA to discriminate glioblastomas from lymphomas and metastases, significantly increasing the specificity from 92.7% to 100%; and maximum percentage of signal intensity recovery-lactate/Cr and maximum percentage of signal intensity recovery-Cho/Cr to discriminate metastases from lymphomas and glioblastomas, significantly increasing the specificity from 83.3% to 97.0% and 100%, respectively.

CONCLUSIONS: Spectroscopy yielded an added performance value to perfusion using optimal combined classifiers of these modalities, significantly increasing the differential diagnostic performances for these common brain tumors.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Vallée A, Guillevin C, Wager M, et al. Added Value of Spectroscopy to Perfusion MRI in the Differential Diagnostic Performance of Common Malignant Brain Tumors. AJNR Am J Neuroradiol. 2018. PMID: 30049719. doi:10.3174/ajnr.A5725

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。